Metabolic · GLP-1
Semaglutide for women: dosing, results, and menopause-specific considerations
Semaglutide (Ozempic, Wegovy) is the most studied GLP-1 receptor agonist in women. Trials show ~15% total body weight loss at 68 weeks with lifestyle support, plus significant improvements in insulin sensitivity, blood pressure, and visceral fat. For menopausal women, it addresses the exact metabolic shift that makes weight loss hard.
Why it works so well in menopause
Semaglutide restores insulin sensitivity, reduces visceral fat preferentially, and quiets food noise — three mechanisms that map directly onto the menopause metabolic shift. Women often describe it as "finally getting my old metabolism back."
Practical protocol
- Baseline labs: A1c, lipids, LFTs, thyroid, TSH.
- Start 0.25 mg weekly; escalate every 4 weeks.
- Protein target 1.2–1.6 g/kg to protect muscle.
- Strength training to preserve lean mass.
- Recheck labs at 3 and 12 months.
What Kindr does
Semaglutide prescribing with lifestyle coaching, coordinated with HRT when indicated. Same-week telehealth across all 50 states.
Frequently asked questions
How much weight will I lose on semaglutide?
Average 15% total body weight at 68 weeks in the STEP trials. Response varies — 10–25% is typical range.
Do women lose more or less weight than men on semaglutide?
Women lose slightly more weight percentage-wise but reach lower absolute loss because starting weight is lower. Response is robust in both sexes.
What is the dose escalation?
Weekly injection: 0.25 mg for 4 weeks, then 0.5, 1.0, 1.7, 2.4 mg — escalating every 4 weeks as tolerated.
What are the main side effects?
Nausea, constipation, fatigue in first 4–8 weeks. Serious risks include pancreatitis, gallbladder disease, and rare thyroid concerns.
Do I regain weight when I stop?
Most people regain most of the weight within a year of stopping. GLP-1s are treatment for a chronic condition, similar to blood pressure medication.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.